A Novel Device for Gestational Diabetes Control

Trial statusNot yet recruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexFemale
Age18-45
SponsorRambam Health Care Campus

About this trial

Rationale of the study: Gestational diabetes mellitus (GDM) is very common and the rate of women suffering from it expected to increase in the next years. It is associated with maternal and fetal morbidity and the risk is correlated to the patient's degree of glucose control which can be achieved through a change in lifestyle or medication. Several studies have demonstrated the effectiveness of mobile apps in improving obstetric outcomes in GDM. In addition, the LUMEN device is a breathing device that produces dietary and exercise recommendations based on CO2 levels and improves metabolic parameters in patients with type 2 diabetes. No work has been done on its effectiveness in treating GDM. Aims of the study: Comparison of metabolic outcomes in women with gestational diabetes, with or without the use of LUMEN app. Design: This will be an open label parallel group 1:1 randomized-controlled trial Methods: the investigators will recruit women diagnosed with GDM. The women will be randomized to the intervention arm that will use the LUMEN device and app or to the control arm that will use a free mobile tracking app. The women will be required to monitor their blood sugar levels daily and to have GDM follow-up in the feto-maternal outpatient clinic, as is customary in GDM. After the birth, the maternal and neonatal outcome will be recorded. Based on past research data, a recruitment of 170 is needed to demonstrate a 16.7% decrease in insulin use to balance diabetes, with α = 0.05 and β = 80.

Eligibility criteria

Qualifiers

Gravidas aged 18-45 years

Singleton pregnancy

Diagnosed with GDM in current pregnancy

First visit to high-risk pregnancy clinic is no late than 32 weeks' gestation

Disqualifiers

Insulin and medications for glycemic control

Antipsychotics

Diuretics

Corticosteroids

Trial design

Treatments tested in this trial

  • Lumen
  • Glucose monitoring mobile app

Treatment groups

120 Participants
are divided into 2 treatment groups

Locations

This trial has no locations

Sponsors and collaborators

Rambam Health Care Campus

Lead sponsor